177 related articles for article (PubMed ID: 21057531)
1. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.
Lui VW; Wong EY; Ho K; Ng PK; Lau CP; Tsui SK; Tsang CM; Tsao SW; Cheng SH; Ng MH; Ng YK; Lam EK; Hong B; Lo KW; Mok TS; Chan AT; Mills GB
Oncogene; 2011 Mar; 30(9):1127-34. PubMed ID: 21057531
[TBL] [Abstract][Full Text] [Related]
2. An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.
Lui VW; Lau CP; Cheung CS; Ho K; Ng MH; Cheng SH; Hong B; Tsao SW; Tsang CM; Lei KI; Yamasaki Y; Mita A; Chan AT
Biochem Pharmacol; 2010 Jun; 79(12):1772-80. PubMed ID: 20219441
[TBL] [Abstract][Full Text] [Related]
3. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
[TBL] [Abstract][Full Text] [Related]
5. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.
Lau PC; Wong EY
Pathol Oncol Res; 2012 Apr; 18(2):357-63. PubMed ID: 21866424
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
Kenessey I; Keszthelyi M; Krámer Z; Berta J; Adám A; Dobos J; Mildner M; Flachner B; Cseh S; Barna G; Szokol B; Orfi L; Kéri G; Döme B; Klepetko W; Tímár J; Tóvári J
Curr Cancer Drug Targets; 2010 May; 10(3):332-42. PubMed ID: 20370683
[TBL] [Abstract][Full Text] [Related]
7. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
8. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
9.
Wong EY; Wong SC; Chan CM; Lam EK; Ho LY; Lau CP; Au TC; Chan AK; Tsang CM; Tsao SW; Lui VW; Chan AT
Oncol Lett; 2015 Feb; 9(2):569-574. PubMed ID: 25621025
[TBL] [Abstract][Full Text] [Related]
10. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
[TBL] [Abstract][Full Text] [Related]
11. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
Wang S; Pashtan I; Tsutsumi S; Xu W; Neckers L
Cell Cycle; 2009 Jul; 8(13):2050-6. PubMed ID: 19502802
[TBL] [Abstract][Full Text] [Related]
12. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-κB pathway modulation.
Zhao M; Fan J; Liu Y; Yu Y; Xu J; Wen Q; Zhang J; Fu S; Wang B; Xiang L; Feng J; Wu J; Yang L
Int J Oncol; 2016 Feb; 48(2):756-64. PubMed ID: 26691054
[TBL] [Abstract][Full Text] [Related]
14. Effect of c-Met inhibitor SU11274 on human colon cancer cell growth.
Gao SH; Liu C; Wei J; Feng Y
Chin Med J (Engl); 2013 Jul; 126(14):2705-9. PubMed ID: 23876900
[TBL] [Abstract][Full Text] [Related]
15. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.
Inagaki Y; Qi F; Gao J; Qu X; Hasegawa K; Sugawara Y; Tang W; Kokudo N
Biosci Trends; 2011; 5(2):52-6. PubMed ID: 21572247
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
Yin L; Kosugi M; Kufe D
Blood; 2012 Jan; 119(3):810-6. PubMed ID: 22117045
[TBL] [Abstract][Full Text] [Related]
17. Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.
Etnyre D; Stone AL; Fong JT; Jacobs RJ; Uppada SB; Botting GM; Rajanna S; Moravec DN; Shambannagari MR; Crees Z; Girard J; Bertram C; Puri N
Cancer Biol Ther; 2014 Sep; 15(9):1129-41. PubMed ID: 24914950
[TBL] [Abstract][Full Text] [Related]
18. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC.
Beizaei K; Gleißner L; Hoffer K; Bußmann L; Vu AT; Steinmeister L; Laban S; Möckelmann N; Münscher A; Petersen C; Rothkamm K; Kriegs M
Head Neck; 2019 Jan; 41(1):208-215. PubMed ID: 30552828
[TBL] [Abstract][Full Text] [Related]
20. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
Mueller KL; Hunter LA; Ethier SP; Boerner JL
Cancer Res; 2008 May; 68(9):3314-22. PubMed ID: 18451158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
